Items where authors include "Akinlade, B."

Article

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (12 more authors) (2021) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology, 184 (5). pp. 857-870. ISSN 0007-0963

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (19 more authors) (2020) Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology, 182 (1). pp. 85-96. ISSN 0007-0963

Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963

de Bruin-Weller, M., Thaçi, D., Smith, C.H. et al. (12 more authors) (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology , 178 (5). pp. 1083-1101. ISSN 0007-0963

Simpson, E.L., Bieber, T., Guttman-Yassky, E. et al. (23 more authors) (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England Journal of Medicine. ISSN 0028-4793